tbuckley/cabot-search huggingface dataset:
Diseases of the Ear, Nose and Throat and Their Accessory Cavities.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
361O Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (Nivo) or Investigator’s Choice (IC): CheckMate 141
Authors: N. Kiyota, K. Harrington, R.L. Ferris, J.W. Shaw, F. Taylor, M. Derosa, D. Turner-Bowker, L. Morrissey, K. Cocks, M. Gillison, J. Guigay
Journal: Annals of Oncology (2016)
AIDS Exceptionalism
Authors: Robert K. Bolan
Journal: Annals of Internal Medicine (1999)

Letters5 January 1999AIDS ExceptionalismRobert K. Bolan, MDRobert K. Bolan, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-1-199901050-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Although time has come for change, the title of Casarett and Lantos' paper (1) ignores history. Special legislation was required to fund AIDS research and care because of the lack of federal leadership early in the epidemic. The Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, which provides access to early-intervention antiretroviral therapy for the uninsured and underinsured, does not specifically fund broad primary and specialty care. Thus, medically appropriate care is often incomplete. It is economically wasteful to invest thousands on a person's complex HIV regimen only to subvert adherence by failing to treat significant comorbid ...References1. Casarett DJ, Lantos JD. Have we treated AIDS too well? Rationing and the future of AIDS exceptionalism. Ann Intern Med. 1998;128:756-9. LinkGoogle Scholar2. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701-29. CrossrefMedlineGoogle Scholar3. Brown I, Demissie K, Burka G, Rhoads GG. In hospital cost savings associated with continuity of care by specialists: an example in HIV-infected inpatients [Abstracts]. Abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, 1-5 February 1998, Chicago. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHave We Treated AIDS Too Well? Rationing and the Future of AIDS Exceptionalism David J. Casarett and John D. Lantos AIDS Exceptionalism Mary Bessesen , Marianne McCollum , and BCBS AIDS Exceptionalism Richard Frothingham AIDS Exceptionalism David Casarett and John Lantos Metrics Cited By“What I Got to Go Through”: Normalization and HIV-Positive Adolescents“AIDS is Money”: How Donor Preferences Reconfigure Local Realities 5 January 1999Volume 130, Issue 1Page: 79KeywordsAIDSAntiretroviral therapyDrugsFearFellowshipsHIVHealth careHealth insuranceLegislationResearch funding Issue Published: 5 January 1999 CopyrightCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.
Authors: Sandra M. Swain, Gong Tang, Charles E. Geyer, Priya Rastogi, James Norman Atkins, Paul P. Donnellan, Louis Fehrenbacher, Catherine A. Azar, Andre Robidoux, Jonathan Polikoff, Adam Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Edith A. Perez, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, Norman Wolmark
Journal: Journal of Clinical Oncology (2012)

LBA1000 Background: The primary aims were to determine whether adjuvant DD AC→PG will be superior to DD AC→P as well as to TAC in DFS and to compare the relative DFS of TAC and DD AC→P. Secondary endpoints include survival and toxicity. Methods: From Nov 3, 2004 to May 3, 2007, 4894 women were randomized; 1630 to TAC (docetaxel [T] 75 mg/m 2 , doxorubicin [A] 50 mg/m 2 , cyclophosphamide [C] 500 mg/m 2 q3 wks x 6), 1634 to DD AC→P (A 60 mg/m 2 and C 600 mg/m 2 q2 wks x 4 followed by P 175 mg/m 2 q2 wks x 4), and 1630 to DD AC→PG (A 60 mg/m 2 and C 600 mg/m 2 q2 wks x 4 → P 175 mg/m 2 + G 2000 mg/m 2 q2 wks x 4). Primary G-CSF support was required and erythropoiesis-stimulating agents (ESA) were used at investigator discretion. 52% were postmenopausal, 65% had 1 - 3 positive nodes, and 80% had HR+ breast cancer. Log-rank tests were used for pair-wise comparisons of the primary (DFS) and secondary (OS) endpoints among the three treatment arms. Results: With 64 months median follow-up, 5-year DFS in DD AC→PG group was 80.6% compared with 82.2% in DD AC→P group (HR=1.1; p=0.27) and 80.1 % (HR=0.97; p=0.71) in TAC group. 5-year OS was 90.8% in DD AC→PG group as compared with 89.1% (HR=.89; p=0.25) in DD AC→P group and 89.6 % (HR=0.90; p=0.32) in TAC group. HR for DFS and OS of DD AC→P vs. TAC were 0.89 (p=0.14) and 1.01 (p=0.92) respectively. Toxicities for TAC, DD AC→P, DD AC→PG, respectively: febrile neutropenia (Gr 3/4: 9%, 4%, 4% [p&lt;0.001]), sensory neuropathy (Gr 3/4: &lt;1%, 7%, 6% [p&lt;0.001]), diarrhea (Gr 3/4: 8 %, 2%, 2% [p&lt;0.001]). Hgb was &lt;10 in 12%, 26%, 33% with ESA use in 35.2%, 47%, 51.6% and transfusions in 3.7%, 6.3%, 9.4%. Deaths on treatment: N=13, 5, 7 (p=0.2). AML/MDS: N=5, 8, 11. All cycles completed in 91% for TAC and 88% for DD regimens. Conclusions: Addition of G to DD AC→P did not improve outcomes. No significant differences in efficacy endpoints were identified between DD AC→P and TAC, though toxicity profiles differed. Funding: NCI PHS U10-CA-37377, -69974, -12027, -69651 and NCCTG U10-CA25224, with additional funding from Eli Lilly &amp; Company, and Amgen, Inc.
Effects of circumferential radiofrequency ablation of pulmonary vein ostia on sympathovagal balance in patients with atrial fibrillation Carlo Pappone, Salvatore Rosanio, Monica Tocchi, Vincenzo Santinelli, Stefano Nardi, Adriano Salvati, Simone Gulletta, Cosimo Dicandia, Gabriele Vicedomini. S. Raffaele University Hospital, Milan, Italy
Journal: Journal of the American College of Cardiology (2001)
Familiality of Polarity at Illness Onset in Bipolar Affective Disorder
Authors: Layla Kassem
Journal: American Journal of Psychiatry (2006)

Objective: Bipolar affective disorder is clinically heterogeneous, and clinical features that run in families may help define more homogeneous phenotypes. The authors sought to establish whether polarity at illness onset, which is related to severity and course, is a familial feature of bipolar affective disorder. Method: The authors studied 971 subjects from 507 families ascertained through sibling pairs with bipolar I or schizoaffective bipolar disorder. Self-reported ages at onset of mania and major depression were used to code polarity at onset as manic, major depressive, or both (mania and major depression in the same onset year). Familial clustering was estimated by using mixed-effects regression analysis, and the relationship between polarity at onset and several other clinical features was assessed. As a preliminary test of genetic validity, the authors assessed the impact of polarity at onset on genetic linkage findings previously detected in this sample. Results: Polarity at onset was significantly familial in this sample. This largely reflected relative pairs concordant for mania at onset, which occurred significantly more frequently than would be expected by chance. Mania at onset substantially increased the genetic linkage signal on chromosome 16p (maximum lod score=4.5) but had no effect on linkage to chromosome 6q. Mania at onset occurred at a later age on average than major depression at onset and was less likely to be complicated by panic attacks or alcoholism. Conclusions: Polarity at illness onset is a familial feature of bipolar affective disorder and is associated with important clinical indicators, which may help define more homogeneous subtypes of bipolar affective disorder.
Dyes and preservatives in oral antihistamines
Authors: R.D. Aldridge, M.E. Smith, R.A. Main
Journal: British Journal of Dermatology (1984)

Journal Article Dyes and preservatives in oral antihistamines Get access R.D. Aldridge, R.D. Aldridge Department of Dermatology, Aberdeen Royal Infirmary R. D. Aldridge, Ward 29, Royal Infirmary, Foresterhill, Aberdeen, Scotland AB9 2ZB. Search for other works by this author on: Oxford Academic Google Scholar M.E. Smith, M.E. Smith Department of Dermatology, Aberdeen Royal Infirmary Search for other works by this author on: Oxford Academic Google Scholar R.A. Main R.A. Main Department of Dermatology, Aberdeen Royal Infirmary Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 110, Issue 3, 1 March 1984, Pages 351–355, https://doi.org/10.1111/j.1365-2133.1984.tb04643.x Published: 01 March 1984 Article history Accepted: 27 August 1983 Published: 01 March 1984
Scintiphotography in congestive heart failure. The disappearing flying bat pattern
Authors: L. Gould
Journal: JAMA (1972)

Liver scintiphotos were obtained of 11 patients in congestive heart failure in order to measure the hepatic and splenic uptake as well as the liver size. When the patients were compensated, the parameters were repeated. During the failure state the scintiphoto revealed an increased spleen to liver uptake, perihepatic background activity, liver enlargement, and bone marrow uptake. These findings have been considered almost pathognomonic of advanced cirrhosis. When cardiac compensation was restored many of these abnormalities were no longer present. Thus, congestive heart failure can produce a liver scintiphoto which can simulate cirrhosis. Further the absence or presence of this pattern depends on the state of cardiac compensation.
A methodological critique of the 'ideal weight' concept
Authors: T. R. Knapp
Journal: JAMA (1983)

This article raises several objections to the procedures that were employed to determine ideal (optimal, desirable) weights in the 1959 and 1979 Build and Blood Pressure studies, the Framingham (Mass) study, and the recent study of the relationship between weight and mortality carried out by the American Cancer Society. The new height-weight tables based on the 1979 Build and Blood Pressure study are also criticized. The article concludes with the recommendation that the concept of ideal weight be abandoned and that attention be devoted to the morbidity and mortality experience of "outliers" (the very thin and the very obese). (<i>JAMA</i>1983;250:506-510)
Nitrates, package inserts, and the Food and Drug Administration. A clinical paradox
Authors: J. Abrams
Journal: JAMA (1981)

A DILEMMA exists regarding the usefulness of long-acting nitrate preparations in patients with angina pectoris or congestive heart failure and the present Food and Drug Administration approved package inserts (regulatory monographs), outlining nitrate dosage regimens and clinical indications. This group of drugs, whether given orally or topically, has been documented to be bioavailable and clinically effective for four to six hours or longer.<sup>1</sup>Yet the FDA continues to classify all oral long-acting nitrate preparations as being only "possibly effective." In addition, maximal dosages currently recommended by the pharmaceutical manufacturers are considerably smaller than the amounts found to be safe, necessary, and efficacious in a variety of recent investigations.<sup>2,3</sup>Finally, promotional literature, including the package insert, may not recommend nitrates for use in vasodilator therapy of congestive heart failure. No pharmaceutical company has yet submitted a New Drug Application to the FDA for use of any long-acting nitrate in
Abstract 2643: TNFAIP2 interacts with EGFR to modulate EGF-induced EGFR auto-phosphorylation and internalization and sequential ERK1/2 activation in nasopharyngeal carcinoma cells
Authors: Hao-Ping Liu, Chih-Ching Wu
Journal: Cancer Research (2019)

Abstract TNFAIP2 (TNF-α-inducible protein 2) is identified as an angiogenic and proinflammatory factor and is essential for formation of tunneling nanotubes connecting between remote cells. Cancer-associated TNFAIP2 overexpression is first demonstrated in nasopharyngeal carcinoma (NPC) and is significantly correlated with poor survival of patients. We previously revealed that TNFAIP2 is associated with actin filaments, inducing actin remodeling and membrane protrusion and promotes cell motility of NPC cells. To elucidate functional roles of TNFAIP2 in cancer progression, we exploited co-immunoprecipitation (co-IP) coupled with mass spectrometry (MS)-based proteomic analysis to identify interacting proteins of TNFAIP2 in NPC cells. Epidermal growth factor (EGF) receptor (EGFR) is one of the identified candidates and is frequently overexpressed in various cancer types. We validated the interaction between TNFAIP2 and EGFR in two types of NPC cell lines; nevertheless, the interaction of TNFAIP2 with EGFR was reduced along with EGF stimulation. Reciprocal domain mapping analyses and immunofluorescence staining further demonstrated that the C-terminal amino acid residues 461-520 of TNFAIP2, which are dispensable for its association with the plasma membrane, are required for TNFAIP2 interaction with EGFR. On the other hand, the intracellular juxtamembrane domain (amino acids 645-689) and kinase domain (amino acids 690-945) of EGFR are needed for its interaction with TNFAIP2. Furthermore, EGF-triggered internalization of EGFR was significantly interfered in TNFAIP2-knockout NPC cells generated using the CRISPR-Cas9 system, accompanied by alleviated auto-phosphorylation of EGFR on the 1068 and 1173 tyrosine residues and subsequent activation of downstream ERK1/2. This impairment of liganded EGFR-transduced signaling in TNFAIP2-knockout NPC cells was correlated with a decrease in cell migration as revealed by transwell migration assays. These data collectively reveal a novel role of TNFAIP2 in modulation of EGF-triggered EGFR activation and sequential signaling transduction through protein-protein interactions. Efforts are made to pursue if the aforementioned events involve modulation of EGFR oligomerization or recruitment of internalized activated EGFR into endosomes. The results could shed light on how TNFAIP2 promotes cancer progression via coordinating with EGFR and the impact of TNFAIP2 on EGFR-targeted cancer therapy. Citation Format: Hao-Ping Liu, Chih-Ching Wu. TNFAIP2 interacts with EGFR to modulate EGF-induced EGFR auto-phosphorylation and internalization and sequential ERK1/2 activation in nasopharyngeal carcinoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2643.
Abstract 1778: 5’-nucleotidases are involved in the biology of human lung cancer cell lines
Authors: Muhammad Zawwad Raza, Octavia Cadassou, Emeline Cros-Perrial, Alain Puisieux, Charles Dumontet, Lars Petter Jordheim
Journal: Cancer Research (2019)

Abstract Cytosolic-5’-nucleotidase II (cN-II) and ecto-5′-nucleotidase (CD73) are enzymes involved in the nucleotide metabolism by dephosphorylating intracellular and extracellular purine nucleotide monophosphates, respectively. Both enzymes have been shown to be involved in cancer by modifying anticancer drug activity, cancer cell biology and immune modulation. To increase the knowledge of cN-II and CD73 roles in cancer cell biology, we developed lung cancer cell models (NCI-H292) with a complete knockout of either or both enzymes using the CRISPR-Cas9 technique. These cell models are used to study cell proliferation and migration, cancer drug sensitivity, cellular behaviour and apoptosis using CFSE staining, IncuCyte relative confluence and wound healing assay, MTT assay, xCELLigence RTCA and caspase-3/7 apoptotic assay. SCID CB17 mice are also used to study the in vivo tumor growth using these cell models. Our results show that there is no significant difference in proliferation between different cell models exposed or not to different concentrations of either adenosine or AMP under normoxic and hypoxic conditions. On the other hand, using xCELLigence RTCA technique, we have observed that CD73-deficient cells have higher cell index as compared to CD73 expressing cells under basal conditions during the first 72 hours of culture. However, adenosine globally decreases the cell index of all NCI-H292 cells, unlike AMP, which influences the cell index of cN-II-deficient cells but not CD73-deficient cells. Under hypoxic condition, cN-II-deficient cells showed higher cell index than the other phenotypes in untreated conditions, whereas cells lacking CD73 showed higher sensitivity to adenosine or AMP. As compared to other phenotypes, CD73 deficient cells are also more sensitive towards vincristine but less sensitive towards mitomycin and fludarabine. These cells are also more prone to adapt to hypoxic conditions and exhibit slower migration rate than their corresponding control cells. However, the effect of adenosine and AMP on migration rate is higher on cN-II-deficient cells. Mice experiments showed no difference in in vivo tumor growth using these cell models. Overall, we show that both CD73 and cN-II are important players in the cell biology of lung cancer cells and in their response to purines. Upcoming experiments should help us understand the molecular mechanisms underlying these observed differences. Citation Format: Muhammad Zawwad Raza, Octavia Cadassou, Emeline Cros-Perrial, Alain Puisieux, Charles Dumontet, Lars Petter Jordheim. 5’-nucleotidases are involved in the biology of human lung cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1778.
BREAST-FED AND BOTTLE-FED BABIES
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pesticides pose concern about children's diet
Authors: C. Marwick
Journal: JAMA (1993)

IN THE LIGHT of "potential concern" that some children may be exposed to unsafe amounts of pesticides in the foods they eat, a committee of the National Research Council is recommending that changes be made in regulating pesticides used on food products to reflect the "unique characteristics of the diets of infants and children." As the council's report was being unveiled last month, the government announced that it intends to reduce the use of pesticides in food products. Three federal agencies are being charged with carrying out this task: the Department of Agriculture, Environmental Protection Agency, and Food and Drug Administration. In its report, the council notes that the exposure of infants and children to dietary pesticides differs both qualitatively and quantitively from that of adults. Consequently, the question is whether the present regulatory approach to controlling residual pesticides in foods is adequate to protect this particularly vulnerable group. The
Magnetic resonance imaging. Prologue. Council on Scientific Affairs
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal